As seen in the graph, there has been a sharp decline in the number of reported cases of both measles and pertussis (whooping cough) since 1980 as a result of vaccines. This statistic shows the number of reported cases of selected vaccine-preventable diseases worldwide, from 1980 to 2023, by disease.

This statistical report, co-authored with the UK Health Security Agency (UKSHA), reports childhood vaccination coverage statistics for England in 2022-23. Data relates to the routine vaccinations offered to all children up to the age of 5 years, derived from the Cover of Vaccination Evaluated Rapidly (COVER). Additional information on children aged 2 and 3 vaccinated against seasonal flu are collected from GPs through UKHSA's ImmForm system.

This publication corresponds to the Common Data Model (CDM) specification of the Baseline Use Case proposed in T.5.2 (WP5) in the BY-COVID project on “SARS-CoV-2 Vaccine(s) effectiveness in preventing SARS-CoV-2 infection.” Research Question: “How effective have the SARS-CoV-2 vaccination programmes been in preventing SARS-CoV-2 infections?” Intervention (exposure): COVID-19 vaccine(s) Outcome: SARS-CoV-2 infection Subgroup analysis: Vaccination schedule (type of vaccine) Study Design: An observational retrospective longitudinal study to assess the effectiveness of the SARS-CoV-2 vaccine in preventing SARS-CoV-2 infections using routinely collected social, health and care data from several countries. A causal model was established using Directed Acyclic Graphs (DAGs) to map domain knowledge, theories and assumptions about the causal relationship between exposure and outcome. The DAG developed for the research question of interest is shown below. Cohort definition: All people eligible to be vaccinated (from 5 to 115 years old, included) or with, at least, one dose of a SARS-CoV-2 vaccine (any of the available brands) having or not a previous SARS-CoV-2 infection. Inclusion criteria: All people vaccinated with at least one dose of the COVID-19 vaccine (any available brands) in an area of residence. Any person eligible to be vaccinated (from 5 to 115 years old, included) with a positive diagnosis (irrespective of the type of test) for SARS-CoV-2 infection (COVID-19) during the period of study. Exclusion criteria: People not eligible for the vaccine (from 0 to 4 years old, included) Study period: From the date of the first documented SARS-CoV-2 infection in each country to the most recent date in which data is available at the time of analysis. Roughly from 01-03-2020 to 30-06-2022, depending on the country. Files included in this publication: Causal model (responding to the research question) SARS-CoV-2 vaccine effectiveness causal model v.1.0.0 (HTML) - Interactive report showcasing the structural causal model (DAG) to answer the research question SARS-CoV-2 vaccine effectiveness causal model v.1.0.0 (QMD) - Quarto RMarkdown script to produce the structural causal model Common data model specification (following the causal model) SARS-CoV-2 vaccine effectiveness data model specification (XLXS) - Human-readable version (Excel) SARS-CoV-2 vaccine effectiveness data model specification dataspice (HTML) - Human-readable version (interactive report) SARS-CoV-2 vaccine effectiveness data model specification dataspice (JSON) - Machine-readable version Synthetic dataset (complying with the common data model specifications) SARS-CoV-2 vaccine effectiveness synthetic dataset (CSV) [UTF-8, pipe | separated, N~650,000 registries] SARS-CoV-2 vaccine effectiveness synthetic dataset EDA (HTML) - Interactive report of the exploratory data analysis (EDA) of the synthetic dataset SARS-CoV-2 vaccine effectiveness synthetic dataset EDA (JSON) - Machine-readable version of the exploratory data analysis (EDA) of the synthetic dataset SARS-CoV-2 vaccine effectiveness synthetic dataset generation script (IPYNB) - Jupyter notebook with Python scripting and commenting to generate the synthetic dataset #### Baseline Use Case: SARS-CoV-2 vaccine effectiveness assessment - Common Data Model Specification v.1.1.0 change log #### Updated Causal model to eliminate the consideration of 'vaccination_schedule_cd' as a mediator Adjusted the study period to be consistent with the Study Protocol Updated 'sex_cd' as a required variable Added 'chronic_liver_disease_bl' as a comorbidity at the individual level Updated 'socecon_lvl_cd' at the area level as a recommended variable Added crosswalks for the definition of 'chronic_liver_disease_bl' in a separate sheet Updated the 'vaccination_schedule_cd' reference to the 'Vaccine' node in the updated DAG Updated the description of the 'confirmed_case_dt' and 'previous_infection_dt' variables to clarify the definition and the need for a single registry per person The scripts (software) accompanying the data model specification are offered "as-is" without warranty and disclaiming liability for damages resulting from using it. The software is released under the CC-BY-4.0 licence, which permits you to use the content for almost any purpose (but does not grant you any trademark permissions), so long as you note the license and give credit.

This statistic shows the annual number of cases of select infectious diseases in the U.S. before and after the development and use of vaccinations as of 2022. Before the use of vaccinations there were an estimated 530,217 new cases of measles per year in the United States. This number dropped to 121 new cases in 2022 due to the development and use of vaccinations.

This dataset contains selected results of rigorous numerical computations described in Section 5 of the paper "Rich bifurcation structure in a two-patch vaccination model" by D.H. Knipl, P. Pilarczyk, G. Röst, published in SIAM Journal on Applied Dynamical Systems (SIADS), Vol. 14, No. 2 (2015), pp. 980–1017, doi: 10.1137/140993934.

Optimization of vaccine allocations among different segments of a heterogeneous population is important for enhancing the effectiveness of vaccination campaigns in reducing the burden of epidemics. Intuitively, it would seem that allocations designed to minimize infections should prioritize those with the highest risk of being infected and infecting others. This prescription is well supported by vaccination theory, e.g. when the vaccination campaign aims to reach herd immunity. In this work, we show, however, that for vaccines providing partial protection (leaky vaccines) and for sufficiently high values of the basic reproduction number, intuition is overturned: the optimal allocation minimizing the number of infections prioritizes the vaccination of those who are least likely to be infected. The work combines numerical investigations, asymptotic analysis for a general model, and complete mathematical analysis in a two-group model. The results point to important considerations in managing vaccination campaigns for infections with high transmissibility.

Methods The MATLAB source code, including all data and parameters used to produce the graphs presented in this work, is available on GitHub at https://github.com/NGavish/HighR0 or Zenodo at https://doi.org/10.5281/zenodo.6962689. The contact matrices used in the code were obtained from [Citation 28; PLOS Computational Biology, e1009098]. There are provided as .mat files under the subdirectory /CountryData and under the names xxx_data.mat where xxx is the country code. Pre-computed data files are provided as .mat files under the subdirectory /data. By default, the graphs are produced from pre-computed simulation output. See Usage Notes for instructions on producing the graphs without relying on these pre-computed data files.

The number of COVID-19 vaccination doses administered per 100 people in the United States rose to 204 as of Oct 27 2023. This dataset includes a chart with historical data for the United States Coronavirus Vaccination Rate.

The development of vaccination by Edward Jenner in 1796 is seen by many as one of the most important and world-changing medical discoveries ever made. Throughout human history, smallpox was responsible for an untold and innumerable share of fatalities, with epidemics devastating countries (and even continents) in their wake; as of 1980, the World Health Organization declared smallpox to be eliminated in nature, making it the only human disease to have been successfully eradicated. If we look at the share of smallpox deaths in England over the nineteenth century, we can see the impact that vaccination had on society during this time. Decline in Britain Within this century, the number of people dying annually from smallpox dropped from 3,000 per million people in the 1700s, to just ten people per million in the 1890s (it is also worth noting that a smallpox pandemic swept across Britain between 1891 and 1893, which caused this number to be higher than it could have been). Mandatory vaccination was not introduced in England until 1853, but by this point the number of smallpox deaths per million people had already fallen to a fraction of its eighteenth century level, and compulsory vaccination reduced these numbers even further.

Covid vaccinated people per hundred people in Iceland, March, 2022 The most recent value is 83.07 Covid vaccinated people per hundred people as of March 2022, an increase compared to the previous value of 82.96 Covid vaccinated people per hundred people. Historically, the average for Iceland from December 2020 to March 2022 is 54.28 Covid vaccinated people per hundred people. The minimum of 1.31 Covid vaccinated people per hundred people was recorded in December 2020, while the maximum of 83.07 Covid vaccinated people per hundred people was reached in March 2022. | TheGlobalEconomy.com

Micronesia, Federated States of's Measles vaccination, % of children vaccinated is 78% which is the 157th highest in the world ranking. Transition graphs on Measles vaccination, % of children vaccinated in Micronesia, Federated States of and comparison bar charts (USA vs. China vs. Japan vs. Micronesia, Federated States of), (Kiribati vs. Grenada vs. Micronesia, Federated States of) are used for easy understanding. Various data can be downloaded and output in csv format for use in EXCEL free of charge.

This dashboard provides an overview of the progress in the roll-out of COVID-19 vaccines in adults (aged 18 years and above) across EU/EEA Member States. It presents the number of vaccine doses distributed by manufacturers to each Member State for the different vaccines authorised for use in the EU and the number of first, second or unspecified doses administered to adult individuals. The information is visualized via interactive maps, graphs and tables. In the near future, it will become possible to also download the raw data.

Data are provided by the EU/EEA Member States via the European Surveillance System (TESSy). Member States are requested to report basic indicators (number of vaccine doses distributed by manufacturers, number of first, second and unspecified doses administered) and data by target groups at national level twice a week (every Tuesday and Friday). Data are subject to retrospective corrections; corrected datasets are released as soon as the processing of updated national data has been completed. For more details, see Notes on the data.

The number of COVID-19 vaccination doses administered in Australia rose to 63681652 as of Oct 27 2023. This dataset includes a chart with historical data for Australia Coronavirus Vaccination Total.

This statistic displays the share of children who received a first dose and a second dose of Measles, Mumps and Rubella (MMR) immunization in England, from 2003/04 to 2023/24. In the year 2023/24, 83.9 percent of children had received their MMR immunization by their fifth birthday.

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases among people who received additional or booster doses were reported from 31 jurisdictions; 30 jurisdictions also reported data on deaths among people who received one or more additional or booster dose; 28 jurisdictions reported cases among people who received two or more additional or booster doses; and 26 jurisdictions reported deaths among people who received two or more additional or booster doses. This list will be updated as more jurisdictions participate. Incidence rate estimates: Weekly age-specific incidence rates by vaccination status were calculated as the number of cases or deaths divided by the number of people vaccinated with a primary series, overall or with/without a booster dose (cumulative) or unvaccinated (obtained by subtracting the cumulative number of people vaccinated with a primary series and partially vaccinated people from the 2019 U.S. intercensal population estimates) and multiplied by 100,000. Overall incidence rates were age-standardized using the 2000 U.S. Census standard population. To estimate population counts for ages 6 months through 1 year, half of the single-year population counts for ages 0 through 1 year were used. All rates are plotted by positive specimen collection date to reflect when incident infections occurred. For the primary series analysis, age-standardized rates include ages 12 years and older from April 4, 2021 through December 4, 2021, ages 5 years and older from December 5, 2021 through July 30, 2022 and ages 6 months and older from July 31, 2022 onwards. For the booster dose analysis, age-standardized rates include ages 18 years and older from September 19, 2021 through December 25, 2021, ages 12 years and older from December 26, 2021, and ages 5 years and older from June 5, 2022 onwards. Small numbers could contribute to less precision when calculating death rates among some groups. Continuity correction: A continuity correction has been applied to the denominators by capping the percent population coverage at 95%. To do this, we assumed that at least 5% of each age group would always be unvaccinated in each jurisdiction. Adding this correction ensures that there is always a reasonable denominator for the unvaccinated population that would prevent incidence and death rates from growing unrealistically large due to potential overestimates of vaccination coverage. Incidence rate ratios (IRRs): IRRs for the past one month were calculated by dividing the average weekly incidence rates among unvaccinated people by that among people vaccinated with a primary series either overall or with a booster dose. Publications: Scobie HM, Johnson AG, Suthar AB, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status — 13 U.S. Jurisdictions, April 4–July 17, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1284–1290. Johnson AG, Amin AB, Ali AR, et al. COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021. MMWR Morb Mortal Wkly Rep 2022;71:132–138. Johnson AG, Linde L, Ali AR, et al. COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination — 24 U.S. Jurisdictions, October 3, 2021–December 24, 2022. MMWR Morb Mortal Wkly Rep 2023;72:145–152. Johnson AG, Linde L, Payne AB, et al. Notes from the Field: Comparison of COVID-19 Mortality Rates Among Adults Aged ≥65 Years Who Were Unvaccinated and Those Who Received a Bivalent Booster Dose Within the Preceding 6 Months — 20 U.S. Jurisdictions, September 18, 2022–April 1, 2023. MMWR Morb Mortal Wkly Rep 2023;72:667–669.

IntroductionVaccine-preventable diseases continue to cause morbidity and mortality despite the introduction of childhood immunizations. Recent media reports from Canada and the United States of America (USA) have highlighted a rise in childhood illnesses like measles, which could have been prevented with vaccines. Parents play a pivotal role in ensuring their children receive timely vaccinations. Immunization reminders can help parents who forget or miss vaccination appointments. In the USA, current literature indicates that Black children have lower vaccination rates than other racialized children and vaccine reminders may improve measles vaccine uptake among Black parents. However, there is limited data in Canada on vaccine uptake in children of Black parents, with evidence suggesting vaccine hesitancy among the Black population.ObjectiveThis scoping review aims to map out existing literature on immunization reminder strategies among parents to identify their impact in improving childhood vaccination rates and promoting child health.Inclusion criteriaThe review will include studies conducted in Canada and the United States of America that focus on immunization reminders for parents who have children under six years and published in English between 2015 and 2025.MethodsDatabase and hand-searching of journals and gray literature will be carried out to retrieve pertinent articles. Studies that meet the inclusion criteria will be eligible for selection. The process of selecting eligible studies will then be summarized on a PRISMA-ScR chart. Collated in data-extraction tables will be authorship information, publication date, methods and findings. The findings, key arguments and themes will be analyzed using a thematic analysis and summarized using a narrative summary.ConclusionThis review will contribute to the existing knowledge on parental preferences for vaccine reminder strategies and their usefulness in increasing childhood vaccination rates. The findings will inform and improve public health strategies aimed at boosting vaccine uptake among children.

The number of COVID-19 vaccination doses administered in Japan rose to 383747738 as of Oct 27 2023. This dataset includes a chart with historical data for Japan Coronavirus Vaccination Total.

This dataset reports the daily reported number of the 7-day moving average rates of Deaths involving COVID-19 by vaccination status and by age group. Learn how the Government of Ontario is helping to keep Ontarians safe during the 2019 Novel Coronavirus outbreak. Effective November 14, 2024 this page will no longer be updated. Information about COVID-19 and other respiratory viruses is available on Public Health Ontario’s interactive respiratory virus tool: https://www.publichealthontario.ca/en/Data-and-Analysis/Infectious-Disease/Respiratory-Virus-Tool Data includes: * Date on which the death occurred * Age group * 7-day moving average of the last seven days of the death rate per 100,000 for those not fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those fully vaccinated * 7-day moving average of the last seven days of the death rate per 100,000 for those vaccinated with at least one booster ##Additional notes As of June 16, all COVID-19 datasets will be updated weekly on Thursdays by 2pm. As of January 12, 2024, data from the date of January 1, 2024 onwards reflect updated population estimates. This update specifically impacts data for the 'not fully vaccinated' category. On November 30, 2023 the count of COVID-19 deaths was updated to include missing historical deaths from January 15, 2020 to March 31, 2023. CCM is a dynamic disease reporting system which allows ongoing update to data previously entered. As a result, data extracted from CCM represents a snapshot at the time of extraction and may differ from previous or subsequent results. Public Health Units continually clean up COVID-19 data, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes and current totals being different from previously reported cases and deaths. Observed trends over time should be interpreted with caution for the most recent period due to reporting and/or data entry lags. The data does not include vaccination data for people who did not provide consent for vaccination records to be entered into the provincial COVaxON system. This includes individual records as well as records from some Indigenous communities where those communities have not consented to including vaccination information in COVaxON. “Not fully vaccinated” category includes people with no vaccine and one dose of double-dose vaccine. “People with one dose of double-dose vaccine” category has a small and constantly changing number. The combination will stabilize the results. Spikes, negative numbers and other data anomalies: Due to ongoing data entry and data quality assurance activities in Case and Contact Management system (CCM) file, Public Health Units continually clean up COVID-19, correcting for missing or overcounted cases and deaths. These corrections can result in data spikes, negative numbers and current totals being different from previously reported case and death counts. Public Health Units report cause of death in the CCM based on information available to them at the time of reporting and in accordance with definitions provided by Public Health Ontario. The medical certificate of death is the official record and the cause of death could be different. Deaths are defined per the outcome field in CCM marked as “Fatal”. Deaths in COVID-19 cases identified as unrelated to COVID-19 are not included in the Deaths involving COVID-19 reported. Rates for the most recent days are subject to reporting lags All data reflects totals from 8 p.m. the previous day. This dataset is subject to change.

Total people vaccinated against Covid in Nicaragua, March, 2023 The most recent value is 6251151 total people vaccinated as of March 2023, an increase compared to the previous value of 6232288 total people vaccinated. Historically, the average for Nicaragua from March 2021 to March 2023 is 4162206 total people vaccinated. The minimum of 0 total people vaccinated was recorded in March 2021, while the maximum of 6251151 total people vaccinated was reached in March 2023. | TheGlobalEconomy.com

This dataset contains the results of the annual report of influenza vaccination rates among healthcare personnel (HCP) with patient contact at healthcare facilities and agencies in New York State. New York Codes, Rules and Regulations, Title 10, Section 2.59 (10 NYCRR Section 2.59). 10 NYCRR Section 2.59 requires any Article 28, 36, or 40 healthcare facility or agency to document the number and percentage of personnel vaccinated against influenza for the current season and report these data to the New York State Department of Health.

Age-standardised mortality rates for deaths involving coronavirus (COVID-19), non-COVID-19 deaths and all deaths by vaccination status, broken down by age group.